



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Examiner Name Peter F. Gade, Jr. Robert M. Kelly  
Sheet 1 of 2 Attorney Docket Number 96700/596

**U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear T <sup>6</sup>
<i>ZMK</i>	1	WO 98/33905	08-06-1998	Isis Innovation Ltd.	
<i>ZMK</i>	2	WO 97/18308	05-22-1997	The Wellcome Trust Ltd. as Trustee of the Wellcome Trust	

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.<sup>6</sup>

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	09/531,969
				Filing Date	March 21, 2000
				First Named Inventor	Jan Gelebter
				Art Unit	1632
				Examiner Name	Peter Paras, Jr. Robert M. Kelly
Sheet	2	of	2	Attorney Docket Number	96700/596

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RMK	3	HUARD J. ET AL., entitled "Myoblast injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction," Journal of Urology, Vol. 159, No. 5, May 30, 1998., page 16, XP002120829, Abstract.			T <sup>2</sup>
	4	CARVALHO A.C. ET AL., entitled "Gap Junctions Formed of Connexin 43 are Found Between Smooth Muscle Cells of Human Corpus Cavernosum," Journal of Urology, Vol. 149, No. 6, 1993, pgs. 1568-1575, XP002273927, Abstract.			
	5	MORENO A. P. ET AL., entitled "Gap Junctions Between Human Corpus Cavernosum Smooth Muscle Cells: Gating Properties and Unitary Conductance," American Journal of			
	6	GROSSMAN H. ET AL., entitled "Decreased Connexin Expression and Intercellular Communication in Human Bladder Cancer Cells," Cancer Research, Vol. 54, No. 11, 1994, pgs. 3062-3065.			
	7	SIEMER C. ET AL., entitled "Characterization of Maxi K Channels in Smooth Muscle Cells From Rat Urinary Bladder," Pfluegers Archiv European Journal of Physiology, Vol. 434, No. 5 Suppl., 1997, p. R102, XP008028610, Abstract.			
	8	DAMASER M. S. ET AL., entitled "Calcium Regulation of Urinary Bladder Function," Journal of Urology, Vol. 157, No. 2, 1997, pgs. 732-738, XP002282784, Abstract.			
RMK	9	LEVIN R.M. ET AL., entitled "Etiology of Bladder Dysfunction Secondary to Partial Outlet Obstruction. Calcium Disregulation in Bladder Power Generation and the Ability to Perform Work," Scandinavian Journal of Urology and Nephrology Supplementum, Vol. 0,			
RMK		No. 184, 1997, pgs. 43-50, XP002282785, Abstract.			

Examiner Signature		Date Considered	12/16/04
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.